Dr. Alexander Hergovich, Toulouse, France
Targeted protein degradation (TPD) and the targeting of protein-protein interactions (PPIs) in a wider sense have emerged as novel drug discovery and development avenues. These approaches can tackle ‘undruggable’ disease drivers (aka provide unprecedented angles for the targeting of disease drivers that are not classically targetable). After providing a broader overview of the TPD & PPI fields, the talk will focus on molecular glues and PROTACs (Proteolysis targeting chimerics) with an emphasis on high throughput screening and subsequent lead identification approaches. The clinical validation status of molecular glues and PROTACs will be summarized with other TPD advances in the clinic.
